A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD
Journal of Attention Disorders · 2024-04 · 28 (6) · 947-956
DOI: 10.1177/10870547241226634 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Attention Disorders, online erschienen am 25.02.2024. Verfasst von Vishal Madaan und 3 weiteren Autor:innen. Beteiligte Einrichtung: American Psychiatric Association, Washington, DC, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Methylphenidate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To compare PRC-063 (multilayer-release methylphenidate) and lisdexamfetamine dimesylate (LDX) on the driving performance of young adults with attention deficit hyperactivity disorder (ADHD) in a randomized, double-blind, crossover study.
Method
Following up to 21 days of each treatment in each treatment course (PRC-063/LDX or LDX/PRC-063), subjects completed a 15-hour driving simulator laboratory assessment. The primary outcome measure was the Tactical Driving Quotient (TDQ) and the Clinical Global Impressions-Improvement (CGI-I) scale was a secondary outcome measure.
Results
Forty-four subjects completed the study. PRC-063 and LDX had equivalent effects on driving performance through a 15-hour time period (least square mean difference −0.3 [standard error 1.08], 95% confidence interval [−2.4, 1.8], p = .793). Consistent improvement in CGI-I was observed. The incidence of treatment-emergent adverse events was similar for each treatment sequence.
Conclusions
PRC-063 and LDX had comparable effects on driving performance, from 1 through 15 hours, the last time point measured.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- American Psychiatric Association, Washington, DC, USA.
- Imbrium Therapeutics L.P., A Subsidiary of Purdue Pharma L.P., Stamford, CT, USA.
- Elvium Life Sciences, Toronto, ON, Canada.
- University of Virginia Health System, Charlottesville, USA.
ORCID-Profile: Graeme A E Donnelly
Zitieren
APA
Madaan, V., Bhaskar, S., Donnelly, G. A. E., & Cox, D. J. (2024). A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD. Journal of Attention Disorders, 28(6), 947-956. https://doi.org/10.1177/10870547241226634
Vancouver
Madaan V, Bhaskar S, Donnelly GAE, Cox DJ. A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD. Journal of Attention Disorders. 2024;28(6):947-956. doi:10.1177/10870547241226634
BibTeX
@article{Madaan2024,
author = {Madaan, Vishal and Bhaskar, Sailaja and Donnelly, Graeme A E and Cox, Daniel J},
title = {A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD},
journal = {Journal of Attention Disorders},
year = {2024},
volume = {28},
number = {6},
pages = {947--956},
doi = {10.1177/10870547241226634}
}
EUVIMED